2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2904

Utility of Untimed Single Urine Protein/Creatinine Ratio As a Substitute for the 24 Hour Proteinuria for the Assessment of Proteinuria in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2455

Utilization and Education of Nurse Practitioners in Pediatric Rheumatology

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ARHP): Pediatrics

9:00AM-11:00AM: Abstract Number: 2528

Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2635

Validating Arthroscopic Findings Using Histology, Status for Erosive Disease, and CRP in RA

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2734

Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2393

Validation of a Web-Based Overlay for Sectoral Scoring of Active Lesions on MRI in Hip Osteoarthritis: Femoral Bone Marrow Lesions Predict Response to Intra-Articular Hyaluronate

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2662

Validation of the Quickdash in the Assessment of Rheumatoid Arthritis Disease Activity

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2388

Variations in Hip Morphology Are Associated with Hip Symptoms: Preliminary Results from a Large Community-Based Cohort

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2694

Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2429

Varicella Vaccination in Patients with Pediatric Rheumatic Diseases Receiving Immunosuppression: Proposal of a Pre-Vaccination Checklist to Ensure Safety

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2799

Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 3046

Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2392

Vibration Perception Threshold and Hip Osteoarthritis in Multicenter Ostoearthritis Study

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2436

Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2648

Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy

Rheumatoid Arthritis - Clinical Aspects Poster Session III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].